B. Macgregor-Cortelli

发表

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.

A. Zelenetz, L. Schwartz, S. Horwitz, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

1009 Phase II clinical experience with the novel proteasome inhibitor bortezomib (formerly PS-341) in patients with indolent and mantle cell lymphomas

A. Zelenetz, O. O’Connor, D. Schenkein, 2003 .

Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier‐type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T‐cell lymphoma

A. Zelenetz, D. Mould, S. Horwitz, 2007, British journal of haematology.

Schedule of bortezomib administration may be an important determinant of single-agent activity in patients with relapsed or refractory follicular (FL) lymphoma and mantle cell lymphoma (MCL)

C. Moskowitz, O. O’Connor, P. Hamlin, 2007 .

Pralatrexate-induced tumor cell apoptosis in the epidermis of a patient with HTLV-1 adult T-cell lymphoma/leukemia causing skin erosions.

G. Nuovo, O. O’Connor, D. Silvers, 2009, Blood.

Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.

V. Seshan, A. Zelenetz, D. Mould, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase ‘2-1-2’ study of two different doses and schedules of pralatrexate, a high affinity substrate for the reduced folate carrier (RFC-1), in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies

D. Mould, S. Horwitz, F. Sirotnak, 2007 .

Drug‐induced cutaneous vasculitis in patients with non‐Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?

D. Esseltine, J. Teruya-Feldstein, M. Gonen, 2006, British journal of haematology.

Importance of Early Splenectomy in Patients with Hepatosplenic T-Cell Lymphoma and Severe Thrombocytopenia

O. O’Connor, J. Zain, B. Macgregor-Cortelli, 2009, Annals of Surgical Oncology.

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

A. Zelenetz, D. Esseltine, M. Stubblefield, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib.

H. Scher, M. Stubblefield, J. Wright, 2006, Clinical oncology (Royal College of Radiologists (Great Britain)).

Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II.

A. Zelenetz, J. Wright, O. O’Connor, 2004, The Journal of the National Comprehensive Cancer Network.

A Multicenter Experience with Single Agent Bortezomib in Non-Hodgkin’s Lymphoma Reveals Marked Differences in Sub-Type Sensitivity to Proteasome Inhibition.

J. Vose, A. Zelenetz, J. Winter, 2004 .